Earnings Results, Website Launch, Stock Price Movement, and Sustainable Strategies - Analyst Notes on Procter & Gamble, Kimberly Clark, Elizabeth Arden, Unilever and Coty

NEW YORK, April 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Procter & Gamble Co. (NYSE: PG), Kimberly-Clark Corporation (NYSE: KMB), Elizabeth Arden, Inc. (NASDAQ: RDEN), Unilever plc (NYSE: UL) and Coty Inc. (NYSE: COTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1665-100free.

--
Procter & Gamble Co. Analyst Notes
On April 23, 2014, The Procter & Gamble Company (P&G) reported its Q3 FY 2014 (period ended March 31, 2014) financial results. The Company reported net sales of $20.6 billion, which remained flat compared with Q3 FY 2013. Diluted net earnings per share were $0.90, up 2.3% YoY. "P&G's third quarter results came in as we had expected. This leaves us on track to deliver our top- and bottom-line growth objectives for the fiscal year," said P&G's Chairman, President and CEO A.G. Lafley. "We're making good progress on our productivity plans, with cost savings and enrollment reductions ahead of going-in targets for the year." For FY 2014, the Company anticipates reported earnings per share to grow in the range of 1% to 4%. The full analyst notes on Procter & Gamble are available to download free of charge at:

http://www.analystsreview.com/1665-PG-28Apr2014.pdf

--
Kimberly-Clark Corporation Analyst Notes
On April 11, 2014, Kimberly-Clark Corporation's subsidiary Kimberly-Clark Health Care (KC Health) announced the launch of a new patient website called, MyCoolief.com. According to the Company, the website is designed to provide patients with information about its COOLIEF* Cooled Radiofrequency Treatment, a minimally invasive and non-surgical outpatient procedure used by interventional pain physicians to target the nerves causing chronic back pain in long-term sufferers. "Four out of five adults in the United States experience chronic lower back pain and Americans spend at least $50 billion each year trying to treat it. It's a very painful and difficult-to-treat chronic condition," said Lisa Kudlacz, General Manager, Interventional Pain Management, Kimberly-Clark Health Care. "COOLIEF offers patients a minimally invasive, safe and effective option to alleviate chronic back pain and help them return to their everyday lives." The full analyst notes on Kimberly Clark are available to download free of charge at:

http://www.analystsreview.com/1665-KMB-28Apr2014.pdf

--
Elizabeth Arden, Inc. Analyst Notes
On April 23, 2014, Elizabeth Arden, Inc.'s (Elizabeth Arden) stock increased 11.92% to end the day at $31.83, compared to the previous day's closing price of $28.44. The Company's stock increased 13.48% over the past three trading days, compared to the Nasdaq Composite which rose 0.77% during the same trading period. The full analyst notes on Elizabeth Arden are available to download free of charge at:

http://www.analystsreview.com/1665-RDEN-28Apr2014.pdf

--
Unilever plc Analyst Notes
On April 8, 2014, Unilever plc (Unilever) reported that its CEO, Paul Polman, has called for decisive action to tackle climate change to secure the future of businesses and people worldwide. "Our current collective response to climate change is inadequate, and this now threatens businesses, jobs and the economy, both in the UK and around the world," said Polman. "Left unchecked, climate change has the potential to become a significant barrier to our growth strategy, and that of just about every other company." The Company informed that it has set clear goals to reduce the environmental footprint of its products, help people to improve their health, and to source 100% of its agricultural raw materials sustainably and to enhance the livelihoods of people across its value chain. The full analyst notes on Unilever are available to download free of charge at:

http://www.analystsreview.com/1665-UL-28Apr2014.pdf

--
Coty Inc. Analyst Notes
On April 23, 2014, Coty Inc.'s (Coty) stock increased 0.70% to end the day at $15.76, compared to the previous day's closing price of $15.65. The Company's stock grew 0.96% over the past five trading days, compared to the Dow Jones Industrial Average which rose 1.47% and to S&P 500 which gained 1.76% during the same period. The full analyst notes on Coty are available to download free of charge at:

http://www.analystsreview.com/1665-COTY-28Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review